Loading…
TEVA-PINDOLOL is a brand name for Pindolol, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Hypertension TEVA-PINDOLOL (pindolol) is indicated for the treatment of mild to moderate hypertension. Pindolol is usually used in combination with other drugs, particularly a thiazide diuretic. However, it may be used alone as an initial agent in those patients in whom, in the judgment of the physician, treatment…
Verbatim from this product's HC label. Tap a section to expand.
Cardiovascular Congestive heart failure (see WARNINGS), severe bradycardia (see WARNINGS), may occur. Syncope, lightheadedness, and postural hypotension. Lengthening of PR interval, second degree AV block, palpitation, chest pains, cold extremities, Raynaud’s phenomenon, claudication, hot flushes.
Very rarely arrhythmia, coronary insufficiency. Central Nervous System Insomnia, nightmares, vivid dreams, fatigue, drowsiness, weakness, dizziness, vertigo, tinnitus, headache, mental depression, nervousness. The following adverse reactions have been reported rarely: aggressiveness, motor disorders, confusion.
Gastrointestinal Diarrhea, constipation, flatulence, heartburn, nausea and vomiting, abdominal pain and dry mouth. Respiratory Shortness of breath and/or dyspnea, wheezing, bronchospasm. Allergic, Dermatological (see WARNINGS) Exanthema, sweating, pruritis, psoriasiform rash.
Eyes Itching, burning, grittiness, dryness. Miscellaneous Muscle cramps, appetite stimulation, weight gain, urinary frequency. Clinical Laboratory On rare occasions, changes in the following parameters were noted: elevated transaminases, alkaline phosphatase, LDH, serum uric acid; reduced bilirubin.
Post-Market Adverse Drug Reactions The following adverse drug reactions are, in most cases, mild and transient in nature and necessity for interruption of pindolol therapy is rarely observed (see WARNINGS and PRECAUTIONS). These adverse drug reactions (Table 1) have been derived from post-marketing experience with pindolol.
Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known. Adverse drug reactions are listed according to system organ classes in MedDRA.
Within each system organ class, ADRs are presented in order of decreasing seriousness. Table 1 Adverse Drug Reactions (frequency not known) 10 Psychiatric disorders Sleep disorders, depression, hallucinations Nervous system disorders Tremor, dizziness, headache Cardiac disorders Bradycardia, conduction disorder, cardiac failure Vascular disorders Hypotension, symptoms of peripheral vascular disorders (peripheral coldness), Raynaud’s-like symptoms Respiratory, thoracic and mediastinal disorders Bronchospasm, dyspnea Gastrointestinal disorders Gastrointestinal disorders (nausea, vomiting, abdominal pain and diarrhea) Skin and subcutaneous tissue disorders Skin reaction, hyperhidrosis, worsening of psoriasis Musculoskeletal and connective tissue disorders Muscle cramps General disorders and administration site conditions Fatigue DRUG INTERACTIONS Table 2 Established or Potential Drug-Drug Interactions Product Ref Effect Clinical Comment Monoamine oxidase (MAO) inhibitors C, T Combining these medications may increase the risk of hypotension, orthostasis, bradycardia, and heart failure due to excessive reduction of sympathetic activity.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Pindolol in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Possibly significant hypertension may theoretically occur up to 14 days following discontinuation of the MAO inhibitor. Monoamine oxidase (MAO) inhibitors may potentiate the pharmacologic effects of beta- blockers, which are thought to competitively antagonize catecholamines at cardiac and other peripheral adrenergic neurons.
Concurrent use with beta- blockers is not recommended. Antidiabetic Agents T Beta-blockers may interfere with the usual hemodynamic response to hyperglycaemia and produce a rise in blood pressure associated with severe bradycardia. Beta-blockade reduces the release of insulin in response to hyperglycemia; therefore, it may be necessary to adjust the dose of antidiabetic drugs.
Beta-blockers should be avoided in unstable diabetic patients (patients who experience wide and unpredictable fluctuations of blood glucose values and/or difficulty in stabilizing blood glucose levels) prone to episodes of hypoglycemia (see 11 Product Ref Effect Clinical Comment WARNINGS and PRECAUTIONS).
g. v. route must be avoided. Oral treatment, if judged absolutely necessary, requires careful monitoring, especially when the beta-blocker is combined with a verapamil- type calcium antagonist. Use with great care with any other calcium antagonists, particularly diltiazem hydrochloride or diltiazem maleate.
g. pronounced bradycardia, sinus arrest, and heart failure) have been observed. Close medical supervision and ECG monitoring, particularly at the beginning of treatment, is recommended (see WARNINGS) Severe reduction in blood pressure and heart failure upon the concomitant administration of dihydropyridine derivatives such as nifedipine with pindolol in patients with latent cardiac insufficiency is possible.
Anti-adrenergic agents T Antihypertensive effect of alpha- adrenergic blockers such as guanethidine, betanidine, reserpine, alpha-methyldopa or clonidine may be potentiated by beta-blockers, which may lead to postural hypotension. When therapy is discontinued in patients receiving a beta-blocker and clonidine concurrently, the beta-blockers should be gradually discontinued several days before clonidine is discontinued, in order to reduce the potential risk of a clonidine withdrawal hypertensive crisis (rebound effect).
Monitoring of blood pressure is recommended during the anti-adrenergics withdrawal. Non-steroidal anti- inflammatory drugs (NSAIDs) T Concomitant administration of non-steroidal anti-inflammatory drugs including COX-2 inhibitors with a beta-blocker, may decrease its antihypertensive effect, possibly as a result of the inhibition of renal prostaglandin Anti-hypertensive effects of beta- blockers may be […]